AnaptysBio, Inc.

AnaptysBio, Inc.

ANABNYSE / NASDAQHealthcareSmall cap

$46.63-$0.77 (-1.6%)

Last close · Data as of Nov 20, 2026

Market cap
$1.5B
EV / EBITDA
17.4x
Revenue
$234.6M
Net margin
-5.6%
ROCE
179.6%

+85.7% over the last year

AnaptysBio, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+2.6%
3M
-17.7%
6M
-22.4%
1Y
+85.7%
5Y
+127.1%

52-week range

Day change -$0.77 (-1.6%) from $47 to $47 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ANAB, bought on each weekday since 2021.

News & filings

What AnaptysBio filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 13.2 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue more than doubled in fiscal 2025.
  • Shareholders' equity is small against the company's size, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.

Read moreShow less

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Sector
Healthcare
Shares outstanding
28.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.5B
P/B
40.4x
EV / EBITDA
17.4x
EV / Sales
5.1x
P/S
6.4x
52-week high
$69.81
52-week low
$25.11

Profitability

Operating margin
20.4%
Net margin
-5.6%
EBITDA margin
29.5%
ROE
-35.6%
ROCE
179.6%
ROA
-3.6%
Asset turnover
0.64

Growth

Revenue
$234.6M
Revenue growth, 1Y
157.0%
Revenue CAGR, 3Y
183.6%
Net profit growth, 1Y
-90.9%
Free cash flow
$19.6M

Solvency

Current ratio
9.07
Debt / Equity
0.38
Debt / Assets
0.04
CFO / Net profit
-1.49
Cash / Market cap
20.7%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$234.6M
Gross profit$234.6M
Operating expenses$186.7M
Research and development$136.0M
Selling, general and administrative$50.7M
Operating income$47.9M
Interest and other-$61.0M
Pretax income-$13.1M
Tax and other$160.0k
Net income-$13.2M

Revenue and net profit

Revenue grew 157.0% in FY2025; net profit is the dashed line.

AnaptysBio, Inc. revenue and net profit by fiscal year
AnaptysBio, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$10.3M-$128.7M
FY2023$17.2M-$163.6M
FY2024$91.3M-$145.2M
FY2025$234.6M-$13.2M

Cash flows

FY2025: $19.7M from operations, $19.6M free after investment (dashed).

AnaptysBio, Inc. operating and free cash flow by fiscal year
AnaptysBio, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$73.6M-$74.0M
FY2023-$120.8M-$121.6M
FY2024-$135.3M-$135.7M
FY2025$19.7M$19.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$234.6M+157.0%1Y
EBITDA
$69.2M
Net profit
-$13.2M
Cash from operations
$19.7M
Free cash flow
$19.6M
Revenue CAGR, 3Y
183.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$234.6M$69.2M-$13.2M$19.6M-35.6%+157.0%-90.9%

Monthly returns

Month-by-month returns of ANAB across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$364.4M
Liabilities$327.2M
Equity$37.2M
Paid-in capital$809.8M
Retained earnings-$772.6M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ANAB highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. AnaptysBio, Inc. (this company)5.1x

Not shown (no positive earnings and no EV / Sales): ArriVent BioPharma, Inc., MBX Biosciences, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
AnaptysBio, Inc.ANABthis company$1.5B—40.4x-35.6%17.4x
Vir Biotechnology, Inc.VIR$1.5B—2.0x-57.2%—
ArriVent BioPharma, Inc.AVBP$1.5B—5.0x-54.1%—
PROCEPT BioRobotics CorporationPRCT$1.5B-16.1x4.2x-26.1%-15.6x
STAAR Surgical CompanySTAA$1.5B-18.5x4.3x-23.4%-36.9x
Perrigo Company plcPRGO$1.5B-1.0x0.5x-48.6%-5.7x
NeoGenomics, Inc.NEO$1.5B-13.6x1.8x-12.9%-44.5x
MBX Biosciences, Inc.MBX$1.5B-16.9x4.0x-23.6%-14.3x
Monte Rosa Therapeutics, Inc.GLUE$1.5B-38.0x6.3x-16.6%-30.0x
Peer median—-16.5x4.1x-24.8%-22.8x

Year-to-date ROI

ANAB since 1 January, against earlier years.

Historical volatility

ANAB's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

AnaptysBio, Inc. operating margin by fiscal year
AnaptysBio, Inc. operating margin by fiscal year
DateOperating margin
FY2022-1119.0%
FY2023-915.3%
FY2024-125.9%
FY202520.4%
LineFY2025
Operating expensesOperating Expense$186.7M
Research and developmentResearch And Development$136.0M
Total expensesTotal Expenses$186.7M
Pretax incomePretax Income-$13.1M

Learn while you research

Academy chapters picked for AnaptysBio, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing157% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →